Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2884)	6/4/2010 11:36:39 AM
From: Jibacoa	1 Recommendation Read Replies (1) \| Respond to of 3722

After making an all time L at the opening this morning, CMED is bouncing up and is now up 17.15% It was up 19.04% at 10:42am Volume of 803Ks is almost 4x its ADV <g> bigcharts.marketwatch.com CMED reported its 4thQ & Yr.end results today. Revenues were down 29.3% but increased by 2.0% sequentially.<g> This is the 3rd time on a roll that revenues have been lower. Earnings were also down 57.2% but up 12.8% on a sequential basis There is no EE for 2011. The EE for 2012 is around $1.70 vs. the $0.87 in 20010 & the $2.18 in 2009 The ACTAY is $15.33 CMED pays a dividend and yield is aroun 4.6% which isn't bad these days.<g> With today's intraday reversal in spite of the general market, it seems that the R/R isn't bad at present levels, and the $15 target could be doable with some good news in the future. bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2884)	6/4/2010 2:44:07 PM
From: Jibacoa	1 Recommendation Read Replies (3) \| Respond to of 3722

Re: ALIM possible competitors. <g> While checking the suggestions offered by some of the Ophthalmologists that answered my question about ALIM's Iluvien, I find that Ophthotech is still private, albeit it seems to have potential.<g> ophthotech.com The other company they mentioned,Thrombogenics, is based in Belgium and trades under symbol THRs in Euronext. Its lead product, microplasmin,is in a PIII for the treatment of vitreomacular adhesion.It is also administered by intaocular injection into the vitreus, Focal vitreomacular adhesion is a condition in which the vitreous gel has an abnormally strong adhesion to the retina. These adhesions can cause vessel and retinal distortion and vitreomacular adhesion is thought to play a key role in numerous retinal conditions such as macular hole formation, and also some forms of macular edema. Vitreomacular adhesion is associated with a much poorer prognosis in patients that suffer from diabetic retinopathy and AMD. medicalnewstoday.com The stock is up today 50% bigcharts.marketwatch.com Bernard